ClinicalTrials.gg

Program

amlenetug

Also written as “Lu AF82422” and “Amlenetug”.

Its studies are mostly in Multiple System Atrophy · Parkinson Disease, led by H. Lundbeck.

Furthest: phase 3, since Nov 22, 20244 company-led studies, 2 open or runningNext primary completion: Feb 17, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck42 open or runningphase 3since Nov 22, 2024Jul 26, 2018Feb 17, 2028phase 3 · NCT06706622

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2018First study: phase 1 study in Parkinson DiseaseFirst studyNCT03611569 · 74 enrolled · United States
  2. Oct 15, 2021Phase 2 study in Multiple System AtrophyNCT05104476 · 64 enrolled · United States, Japan
  3. Feb 6, 2024Phase 1 study in Healthy ParticipantsNCT06258720 · 24 enrolled · China
  4. Nov 22, 2024Phase 3 study in Multiple System AtrophyNCT06706622 · 401 enrolled · United States, Australia, Canada and more

Ahead

  1. Feb 17, 2028Primary completion: phase 3 study in Multiple System AtrophyNCT06706622

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06706622Multiple System Atrophy · United States, Australia, Canada and more3Active, not recruitingFeb 17, 2028401
NCT06258720Healthy Participants · China1CompletedSep 3, 202424
NCT05104476Multiple System Atrophy · United States, Japan2Active, not recruitingNov 16, 202364
NCT03611569Parkinson Disease · United States1CompletedJul 26, 202174

How it is read

Names in the registry

  • “Lu AF82422”, 3 entries
  • “Amlenetug”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.